| Original language | English (US) |
|---|---|
| Pages (from-to) | 469 |
| Number of pages | 1 |
| Journal | Clinical Gastroenterology and Hepatology |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2022 |
Bibliographical note
Funding Information:Conflicts of interest These authors disclose the following: David M. Faleck has received consulting fees from Kaleido Biosciences. Jean-Frederic Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Galxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, and Vifor; and holds stock options in Intestinal Biotech Development. The remaining author discloses no conflicts.
PubMed: MeSH publication types
- Letter
- Comment